Table 2 Selected malaria vaccine candidates currently under preclinical development or in clinical trials.
From: Malaria vaccines since 2000: progress, priorities, products
Vaccine candidate | Immunogen type | Current status |
|---|---|---|
Pre-erythrocytic stage (anti-infection) | ||
RTS,S | Subunit | Phase 4 |
R21 | Subunit | Phase 1/2 |
Full-length CSP | Subunit | Phase 1 |
PfSPZ Vaccine | Whole sporozoite (radiation attenuation) | Phase 2 |
Chemoprophylaxis vaccination (CVac) | Whole sporozoite (chemical attenuation) | Phase 2 |
Genetically attenuated parasite (GAP) vaccines | Whole sporozoite (genetic attenuation) | Phase 1 |
Blood stage | ||
PfRH5 | Subunit | Phase 1 |
AMA1-RON2 | Subunit | Preclinical |
PfSEA-1 | Subunit | Preclinical |
PfGARP | Subunit | Preclinical |
Chemically attenuated parasite (CAP) vaccines | Whole blood-stage parasite | Phase 1 |
VAR2CSA (Placental malaria) | Subunit | Phase 1 |
PvDBP (Plasmodium vivax) | Subunit | Phase 1 |
Mosquito stage (Transmission-blocking) | ||
Pfs25 | Subunit | Phase 1 |
Pfs230 | Subunit | Phase 2 |
Pfs48/45 | Subunit | Preclinical |
Pvs230 (Plasmodium vivax) | Subunit | Preclinical |
